Icon

MAYZENT (nda209884)- (EQ 0.25MG BASE,EQ 2MG BASE,EQ 1MG BASE)

SIPONIMOD NOVARTIS
EQ 0.25MG BASE,EQ 2MG BASE,EQ 1MG BASE
Yes No
2036-Jul-24 2024-Mar-26
None None
None No
MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
0 0 0
Total Other Developers 8
Drugs with Suitability No
EQ 0.25MG BASE ** ** - - -
EQ 2MG BASE ** ** - - -
EQ 1MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.